MATTHEW SCHULTZ: Open Payments
NPI 1043804966 · HUNTINGDON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$528 in 25 payments from 10 companies in 2025. Trend: 2023 $302 · 2024 $676 · 2025 $528
Food & beverage: $451Education: $77
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $105 |
| Janssen Biotech, Inc. | 1 | $77 |
| Aimmune Therapeutics, Inc. | 4 | $71 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $62 |
| Phathom Pharmaceuticals, Inc. | 3 | $44 |
| Ardelyx, Inc. | 2 | $38 |
| Ipsen Biopharmaceuticals, Inc | 2 | $37 |
| PFIZER INC. | 2 | $32 |
| ABBVIE INC. | 2 | $31 |
| Lilly USA, LLC | 2 | $30 |
Products named: ENTYVIO, TREMFYA, XIFAXAN, ZENPEP, VOQUEZNA, IBSRELA, IQIRVO, VELSIPITY.
Industry payments across PA — which companies pay providers there.
